Paul B. Chapman
Chief Medical Research Officer
Credentials: · · · ·
History
Present
Memorial Sloan Kettering Cancer
- 1981–1984
University of Chicago Hospitals and Clinics
Research
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
New England Journal of Medicine · 2011 · First of 29 authors · Corresponding · 6,152 citations
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Nature Medicine · 2012 · 3,039 citations
Inhibition of mutated, activated BRAF in metastatic melanoma
New England Journal of Medicine · 2010 · Last of 11 authors · 2,847 citations
63 papers
- AH
41 papers
32 papers · 5 as a fellow
29 papers · 5 as a fellow
- AS
26 papers · 9 as a fellow
- RC
24 papers
- PM
19 papers · 8 as a fellow
- PL
19 papers
Grants
- 2006–2009
Phase II Trial of 17-AAG in Melanoma Patients
National Cancer Institute · R21
Contact PI · $724.1K · Sloan-Kettering Inst Can Research
- 2003–2008
Anti-GD3 NKT Cells as Effector Cells Against Melanoma
National Cancer Institute · R01
Contact PI · $1.1M · Sloan-Kettering Inst Can Research
- 1999–2005
Immunization Against Tumor Cell Antigens
National Cancer Institute · K24
Contact PI · $532.1K · Sloan-Kettering Inst Can Research
- 1998–2001
Immunization with bec2 Antiid Vaccine and gd3-Lactone
National Cancer Institute · R21
Contact PI · $279.1K · Sloan-Kettering Inst Can Research
Clinical trials
- 2026–2027
Principal investigator · Recruiting
Weill Medical College of Cornell University
- 2019–2022
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
- 2017–2020
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
- 2013–2016
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center